A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Trial Profile

A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 May 2018

At a glance

  • Drugs Asciminib (Primary) ; Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 30 Apr 2018 Planned End Date changed from 2 May 2022 to 20 Dec 2022.
    • 30 Apr 2018 Planned primary completion date changed from 2 May 2022 to 20 Dec 2022.
    • 22 Feb 2018 Planned number of patients changed from 250 to 290.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top